Zacks Investment Research cut shares of Histogenics (NASDAQ:HSGX) from a hold rating to a sell rating in a research report released on Wednesday.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

Several other brokerages have also issued reports on HSGX. HC Wainwright reiterated a buy rating and issued a $3.50 price objective on shares of Histogenics in a research report on Monday, August 13th. Brookline Cap M reiterated a buy rating on shares of Histogenics in a research report on Wednesday, August 1st. Needham & Company LLC boosted their price objective on Histogenics to $5.00 and gave the company a buy rating in a research report on Thursday, September 6th. Finally, BTIG Research lowered Histogenics from a buy rating to a neutral rating and set a $3.50 price objective for the company. in a research report on Wednesday, September 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Histogenics presently has a consensus rating of Hold and a consensus price target of $3.25.

Shares of HSGX opened at $0.51 on Wednesday. Histogenics has a 52-week low of $0.50 and a 52-week high of $3.35. The company has a market capitalization of $15.64 million, a P/E ratio of -0.52 and a beta of 1.02.

Histogenics (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.05). Research analysts anticipate that Histogenics will post -0.83 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in HSGX. JPMorgan Chase & Co. acquired a new position in Histogenics during the 1st quarter worth approximately $320,000. BlackRock Inc. boosted its position in Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 22,927 shares during the last quarter. Renaissance Technologies LLC boosted its position in Histogenics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock worth $961,000 after acquiring an additional 22,133 shares during the last quarter. Finally, DRW Securities LLC acquired a new position in Histogenics during the 2nd quarter worth approximately $242,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Recommended Story: Liquidity

Get a free copy of the Zacks research report on Histogenics (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Histogenics (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.